Merck & Co., Inc. (MRK) Reports 56%–63% MASH Resolution at 52 Weeks

What happened

Merck said its Phase 2b trial of efinopegdutide met its main goal: MASH resolution without worsening fibrosis at 52 weeks occurred in 56%, 63% and 61% of participants across doses, compared with 13% on placebo. Fibrosis improvement ranged from 34% to 52%, versus 21% on placebo.

Confirmed

Global impact / market context

The results suggest efinopegdutide may have treatment potential, but they come from a Phase 2b study and do not establish approval or commercial demand. If later studies confirm benefit and acceptable tolerability, Merck could have a new product opportunity; development costs and trial outcomes remain important uncertainties.

Analyst inference

The trial showed higher disease-resolution and fibrosis-improvement rates with efinopegdutide than with placebo, alongside more discontinuations due to adverse events. If these findings persist in later studies, efficacy and tolerability could shape Merck’s development decisions and future spending on the candidate.

Analyst inference

What to watch

1. Look for later clinical trials to test whether efinopegdutide’s improvements in MASH resolution and fibrosis persist in larger or longer studies; the article gives no results beyond 52 weeks. Analyst inference
2. Track whether further results report adverse-event discontinuations by dose and how they compare with placebo, since tolerability may affect continued treatment use. Analyst inference
3. Watch for regulatory progress and evidence of approval; the article says further development and regulatory outcomes are needed before the candidate’s commercial prospects can be established. Analyst inference

Evidence

• Original source link unavailable